Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Sales (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Return on Sales for 4 consecutive years, with 4.64% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 439.0% to 4.64% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.37% through Dec 2025, down 21.0% year-over-year, with the annual reading at 10.37% for FY2025, 21.0% down from the prior year.
  • Return on Sales hit 4.64% in Q4 2025 for Taysha Gene Therapies, up from 14.92% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 6205.62% in Q1 2022 to a low of 17.88% in Q2 2024.
  • Historically, Return on Sales has averaged 388.06% across 4 years, with a median of 5.64% in 2024.
  • Biggest five-year swings in Return on Sales: crashed -620937bps in 2023 and later surged 534bps in 2025.
  • Year by year, Return on Sales stood at 42.2% in 2022, then tumbled by -110bps to 4.17% in 2023, then plummeted by -116bps to 9.03% in 2024, then surged by 49bps to 4.64% in 2025.
  • Business Quant data shows Return on Sales for TSHA at 4.64% in Q4 2025, 14.92% in Q3 2025, and 12.54% in Q2 2025.